🇺🇸 FDA
Patent

US 10364295

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10364295 (Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers) held by PRECISION BIOLOGICS, INC. expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PRECISION BIOLOGICS, INC.
Grant date
Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/39558, A61K45/06